GeneDx Holdings Corp.

WGS Nasdaq SEC CIK 1818331
Follow GeneDx Holdings Corp. Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $123.1M +5.4% vs same quarter last year
Net income −$12.3M −61.5% vs same quarter last year
EPS, diluted −$0.41 −51.9% vs same quarter last year
Operating cash flow −$10.6M −167.2% vs same quarter last year
Revenue by quarter
$95.6M
$87.1M
$102.7M
$116.7M
$121M
$102.3M
$114.4M
$123.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$750M−$500M−$250M$0$250M$500MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$427.5M−$21M
FY24$305.5M−$52.3M
FY23$202.6M−$175.8M
FY22$234.7M−$549M
FY21$212.2M−$245.4M
FY20$179.3M−$241.3M
FY19$196.2M−$29.7M
FY18--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−300%−200%−100%0%100%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2569.7%−3.1%−4.9%
FY2463.6%−7.6%−17.1%
FY2344.4%−89.2%−86.8%
FY22−11.4%−284.5%−233.9%
FY21−7.8%−210.3%−115.6%
FY202.2%−134.9%−134.6%
FY1942.2%−15.5%−15.1%
FY18---
Free cash flowOperating cash flow minus capital expenditure
−$400M−$300M−$200M−$100M$0$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25$14.3M
FY24−$34M
FY23−$185.4M
FY22−$326.3M
FY21−$199.8M
FY20−$117.2M
FY19−$30.7M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • GeneDx Holdings Corp.
  • Healthcare median
−300%−200%−100%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGeneDx Holdings Corp.Healthcare median
FY25−4.9%−30.6%
FY24−17.1%−47%
FY23−86.8%−58%
FY22−233.9%−80.4%
FY21−115.6%−71.9%
FY20−134.6%−62.2%
FY19−15.1%−46.3%
FY18-−49.6%